On September 3rd, the office building of Gansu Plant-Based Innovation Technology Co., Ltd., a subsidiary of Shanghai Unicornshell Pharmaceutical Technology Co., Ltd., successfully reached its structural completion, followed by a grand topping-out ceremony. Attendees included representatives from the Shandan Project Company, the supervising unit, and all members of the general contractor. Located in Shandan County, Zhangye City, Gansu Plant-Based Innovation Technology Co., Ltd. is a vital component of Unicornshell's Northwest Industrial Cluster strategy. The successful topping-out of the office building signifies the project's transition from the main construction phase to secondary structures and interior finishing, laying a solid foundation for subsequent production workshop construction and trial production.

During the ceremony, all participating parties highly commended the project's progress. The topping-out of the office building represents a significant milestone, and they pledged to advance subsequent production workshop and supporting facility construction strictly according to the schedule. All parties will accelerate efforts to ensure the project's full completion on time, aiming for early mass production and operational launch. 

Guided by its corporate mission to “Promote Medication Safety and Safeguard Human Health,” Unicornshell specializes in developing plant-based pharmaceutical excipients. Utilizing non-animal-derived raw materials such as plant cellulose and potato starch, combined with proprietary patented processes, the company has developed plant-based capsules and a series of related products. These offerings feature high safety, excellent biocompatibility, and superior stability, making them ideal alternatives to gelatin capsules for widespread application in pharmaceuticals, health supplements, and food products.

Furthermore, Unicornshell pursues a dual-track strategy: continuously advancing breakthroughs in plant-based capsules to provide green, safe, and internationally compliant excipient solutions; and leveraging Gansu's premium authentic Chinese herbal materials to develop innovative oral-disintegrating films for traditional Chinese medicine, expanding new application scenarios for traditional Chinese medicine formulations. This dual-drive approach not only propels the modernization of traditional Chinese medicine but also highlights the strategic value of Gansu's herbal resources within the company's national layout.

The smooth progress of the Gansu project will provide robust support for Unicornshell's northwest industrial cluster development, while laying a solid foundation for nationwide industrial network synergy, product system refinement, and market expansion. Unicornshell will persist in its “green, safe, and intelligent” development strategy, driving the upgrading of the green pharmaceutical industry and contributing to global health initiatives.